Jazz Pharmaceuticals Receives Positive CHMP Opinion for Solriamfetol to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adults with Narcolepsy or Obstructive Sleep Apnea
- Friday, November 15, 2019, 7:18
- Business
- Add a comment
DUBLIN, Nov. 15, 2019 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the marketing authorisation of solriamfetol to improve…
About the Author
adminasapcorp has written 41806 stories on this site.